Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Cixutumumab is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cixutumumab||IMC-A12||IGF1R Antibody 8||Cixutumumab (IMC-A12) is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (PMID: 29520435, PMID: 29909907).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||head and neck squamous cell carcinoma||no benefit||Cixutumumab||Phase II||Actionable||In a Phase II trial, Cixutumumab (IMC-A12) treatment resulted in a median progression-free survival (PFS) of 1.9 months, a 6-month PFS rate of 6%, an objective response rate of 2%, a clinical benefit rate of 19% (n=47; 1 complete response, 8 stable disease), and a median overall survival (OS) of 5.3 months in metastatic head and neck squamous cell carcinoma patients, and did not result in an improved PFS or OS compared to historical Erbitux (cetuximab) treatment alone (PMID: 29909907).||29909907|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT00957853||Phase II||Cetuximab Cixutumumab||Preoperative Treatment With Cetuximab and/or IMC-A12||Completed||USA||0|
|NCT01263782||Phase II||Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab||BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer||Completed||USA||0|